Clinical Trial Update: A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing Pfizer's PF-00299804 (dacomitinib) to erlotinib in advanced non-small cell lung cancer that progressed after one or two pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• PF-00299804

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-08-21